Literature DB >> 8808429

Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression.

F Hirano1, H Tanaka, Y Makino, K Okamoto, I Makino.   

Abstract

We investigated the effect of ursodeoxycholic acid on major histocompatibility complex class I gene expression in cultured human hepatoma cells. Ursodeoxycholic acid, which is now being used for the treatment of various autoimmune liver diseases, paradoxically increased the mRNA level of major histocompatibility complex class I. However, endogenous bile acids, for example, chenodeoxycholic acid, increased major histocompatibility complex class I mRNA expression more strongly compared with ursodeoxycholic acid. Concerning the interplay between ursodeoxycholic and chenodeoxycholic acids, these bile acids additively induced major histocompatibility complex class I mRNA expression. In contrast, when the total concentration of ursodeoxycholic and chenodeoxycholic acids was kept constant, the expression of major histocompatibility complex class I mRNA appeared to decrease in a dose-dependent manner with an increasing ratio of ursodeoxycholic acid. These findings indicate that the beneficial action of ursodeoxycholic acid may be related to this relative decrease in major histocompatibility complex class I gene expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808429     DOI: 10.1007/bf01211187

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  40 in total

1.  Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid.

Authors:  Y Calmus; P Gane; P Rouger; R Poupon
Journal:  Hepatology       Date:  1990-01       Impact factor: 17.425

2.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

3.  HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease.

Authors:  G Ballardini; F B Bianchi; R Mirakian; M Fallani; E Pisi; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

4.  Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

Authors:  P R Galle; L Theilmann; R Raedsch; G Otto; A Stiehl
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

5.  Regulation of the major histocompatibility complex class I mRNA expression by bile acids in cultured human hepatoma cells.

Authors:  F Hirano; H Tanaka; Y Makino; K Okamoto; M Inaba; T Miura; I Makino
Journal:  Biochem Biophys Res Commun       Date:  1995-03-28       Impact factor: 3.575

6.  Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes.

Authors:  D M Heuman; W M Pandak; P B Hylemon; Z R Vlahcevic
Journal:  Hepatology       Date:  1991-11       Impact factor: 17.425

7.  Increased expression of major histocompatibility antigens in the liver as a result of cholestasis.

Authors:  G K Innes; Y Nagafuchi; B J Fuller; K E Hobbs
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939

8.  Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.

Authors:  Y Chretien; R Poupon; M F Gherardt; O Chazouilleres; D Labbe; A Myara; F Trivin
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

9.  Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes.

Authors:  G Bouchard; I M Yousef; B Tuchweber
Journal:  Liver       Date:  1993-08

10.  Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.

Authors:  R E Poupon; E Eschwège; R Poupon
Journal:  J Hepatol       Date:  1990-07       Impact factor: 25.083

View more
  2 in total

Review 1.  The management of primary sclerosing cholangitis.

Authors:  Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2003-02

2.  Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review.

Authors:  Jillian Reardon; Trana Hussaini; Majid Alsahafi; Vladimir Marquez Azalgara; Siegfried R Erb; Nilufar Partovi; Eric M Yoshida
Journal:  J Clin Transl Hepatol       Date:  2016-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.